



April 17, 2017

Arena Pharmaceuticals Announces Multiple Presentations at ASPET 2017 at Experimental Biology

- Data to highlight etrasimod, Arena's orally available next generation sphingosine-1-phosphate (S1P) receptor modulator for the potential treatment of autoimmune diseases -

SAN DIEGO, April 17, 2017 /PRNewswire/ -- [Arena Pharmaceuticals, Inc.](#) (NASDAQ: ARNA), a biopharmaceutical company focused on developing novel, small molecule drugs across multiple therapeutic areas, today announced three data presentations on etrasimod (APD334) at [ASPET 2017 at Experimental Biology](#) (EB). The conference is taking place April 22-26 at McCormick Place Convention Center in Chicago, IL.

The presentations encompass preclinical data highlighting the potent and selective immunomodulatory effects of etrasimod in inflammatory bowel disease (IBD), including ulcerative colitis (UC).

The following abstracts will be presented:

Title: *Etrasimod, a Novel Sphingosine-1-Phosphate Receptor (S1PR1) Modulator, Lacks Functional Activity at S1P2 Receptors*

Day of presentation: Sunday, April 23, 2017

Abstract Number: 6502

Poster Session Title: Cell Signaling and Cancer Therapeutics

Poster Board Number: D148

Location: McCormick Place Convention Center, Hall F

Title: *Etrasimod (APD334), an Oral, Next-Generation Sphingosine-1-Phosphate Receptor Modulator Inhibits the Development of Colitis in Lymphoid-Null Mice Injected with Colitogenic CD4+ T Cells*

Day of presentation: Tuesday, April 25, 2017

Abstract Number: 6337

Poster Session Title: Drug Discovery and Development: Immunomodulation and Inflammation

Poster Board Number: D125

Location: McCormick Place Convention Center, Hall F

Title: *Functional Activity of Etrasimod and a Diverse Panel of Sphingosine-1-Phosphate Receptor (S1PR1) Modulators at S1P4 Receptors*

Day of presentation: Tuesday, April 25, 2017

Abstract Number: 6545

Poster Session Title: Drug Discovery and Development: Immunomodulation and Inflammation

Poster Board Number: D126

Location: McCormick Place Convention Center, Hall F

About Arena Pharmaceuticals

[Arena Pharmaceuticals](#) is a biopharmaceutical company focused on developing novel, small molecule drugs with optimized receptor pharmacology designed to deliver broad clinical utility across multiple therapeutic areas. Our proprietary pipeline includes potentially first- or best-in-class programs for which we own global commercial rights. Our three most advanced investigational clinical programs are [ralinepag](#) (APD811) in Phase 2 evaluation for pulmonary arterial hypertension (PAH), [etrasimod](#) (APD334) in Phase 2 evaluation for multiple autoimmune indications, and [APD371](#) in Phase 2 evaluation for the treatment of pain associated with Crohn's disease. In addition, Arena has collaborations with the following pharmaceutical companies: Eisai Co., Ltd. and Eisai Inc. (commercial stage), Axovant Sciences (Phase 2 candidate), and Boehringer Ingelheim International GmbH (preclinical candidate).

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the upcoming presentation; Arena's focus, and the potential of its programs and collaborations. For such statements, Arena claims the protection of the Private Securities Litigation Reform

Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include those disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Contact: Arena Pharmaceuticals, Inc.
Kevin R. Lind, Chief Financial Officer
klind@arenapharm.com
858.210.3636



To view the original version on PR Newswire, visit: <http://www.prnewswire.com/news-releases/arena-pharmaceuticals-announces-multiple-presentations-at-aspet-2017-at-experimental-biology-300440006.html>

SOURCE Arena Pharmaceuticals, Inc.

News Provided by Acquire Media